Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE) Meeting Abstract
| Authors: | Patel, J. N.; Jiang, C.; Hertz, D. L.; Mulkey, F. A.; Friedman, P. N.; Halabi, S.; Ratain, M. J.; Morris, M. J.; Small, E. J.; Owzar, K.; Kelly, W. K.; McLeod, H. L. |
| Abstract Title: | Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE) |
| Meeting Title: | 105th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 74 |
| Issue: | 19 Suppl. |
| Meeting Dates: | 2014 Apr 5-9 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2014-10-01 |
| Language: | English |
| ACCESSION: | WOS:000349910201330 |
| DOI: | 10.1158/1538-7445.am2014-3841 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3841 -- 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 05-09, 2014 -- San Diego, CA -- S -- Source: Wos |
